Principles of Antiretroviral Treatment of Children and Adolescents with Human Immunodeficiency Virus Infection

Seminars in Pediatric Infectious Diseases

Volumn 14, Issue 4, 2003, Pages 269-285

  Havens, Peter L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VIDEX EC; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BONE NECROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; DYSPHAGIA; ERYTHEMA MULTIFORME; FATIGUE; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTE COUNT; MALAISE; MANIA; MEGALOCYTOSIS; METABOLIC DISORDER; MOUTH DISEASE; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPENIA; OSTEOPOROSIS; PALATABILITY; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACOKINETICS; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RASH; RETINOPATHY; REVIEW; RISK BENEFIT ANALYSIS; SLEEP DISORDER; SYMPTOM; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION; XEROSTOMIA;

EID: 0942276966     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2003.09.005     Document Type: Article

References (116)

1. Saitoh A, Hsia K, Fenton T, et al: Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 185:1409-1416, 2002
2. De Rossi A, Walker AS, DeForni D, et al: Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy. AIDS 16:1961-1963, 2002
3. Carpenter C: Initial antiretroviral regimens. BMJ 324:747-748, 2002
4. Jordan R, Gold L, Cummins C, et al: Systemic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324:757-760, 2002
5. Sharland M, Gibb D, Giaquinto C, et al: Current evidence for the use of paediatric antiretroviral therapy - A PENTA analysis. Eur J Pediatr 159:649-656, 2000
6. Nachman SA, Stanley K, Yogev R, et al: Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children. A randomized controlled trial. JAMA 283:491-498, 2000
7. Yogev R, Lee S, Wiznia A, et al: Stavudine, nevirapine, and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J 21:119-125, 2002
8. Saez-Llorens X, Nelson RP, Emmanuel PA randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. Pediatrics 107:1-11, 2001
9. Krogstad P, Lee S, Johnson G, et al: Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immumodeficiency virus type 1. Clin Infect Dis 34:991-1001, 2002
10. Hammer SM, Vaida F, Bennett KK, et al: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 288:169-180, 2002
11. Centers for Disease Control and Prevention: Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Recomm Rep 47:1-42, 1998
12. Centers for Disease Control and Prevention: Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 51:1-55, 2002
13. Sharland M, di Zub GC, Ramos JT, et al: PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med 3:215-226, 2002
14. Palumbo PE: Antiretroviral therapy of HIV infection in children. Pediatr Clin North Am 17:155-169, 2000
15. Yeni PG, Hammer SM, Carpenter CCJ, et al: Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235, 2002
16. World Health Organization: Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. WHO, 2002. Available from URL: http://www.who.int/hiv/topics/arv/ISBN9241545674.pdf
17. Melvin AJ, Rodrigo AG, Mohan KM, et al: HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol 20:168-473, 1999
18. Spector SA, Hsia K, Yong FH, et al: Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis 182:1769-1773, 2000
19. Gortmaker SL, Hughes M, Cervia J, et al: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 345:1522-1528, 2001
20. DeMartino M, Tovo PA, Balducci M, et al: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 284:190-197, 2000
21. Saulsbury FT: Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 32:464-468, 2001
22. Canani RB, Spagnuolo MI, Cirillo P, et al: Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy. AIDS 13:1005, 1999
23. Paediatric European Network for Treatment of AIDS (PENTA): Five year follow-up of vertically HIV infected children in a randomized double blind controlled trial of immediate versus deferred zidovudine: The PENTA 1 trial. Arch Dis Child 84:230-236, 2001
24. Patella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860, 1998
25. Lindsey JC, Hughes MD, McKinney RE, et al: Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis 182:1385-1393, 2000
26. Buchacz K, Cervia JS, Lindsey JC, et al: Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 108:1-7, 2001
27. Miller T, Mawn BE, Orav EJ, et al: The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 107:1-6, 2001
28. Dreimane D, Nielsen K, Deveikis A, et al: Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1 infected children. Pediatr Infect Dis J 20:315-316, 2001
29. Verweel G, van Rossum AMC, Hartwig NG, et al: Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 109:1-7, 2002
30. Van Rossum AMC, Scherpbier HJ, van Lochem EG, et al: Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 15:2267-2275, 2001
31. Resino S, Sanchez-Ramon S, Bellon MJ, et al: Immunological recovery after three years antiretroviral therapy in HIV-1-infected children. AIDS 16:483-486, 2002
32. Correa R, Munoz-Fernandez A: Effects of highly active antiretroviral therapy on thymical reconstitution of CD4 T lymphocytes in vertically HIV-infected children. AIDS 16:1181-1183, 2002
33. Berkelhamer S, Borock E, Elsen C, et al: Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 32:1090-1004, 2001
34. Palumbo PE, Raskino C, Fiscus S, et al: Virologic and immunologic response to nucleoside reverse transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. J Infect Dis 179:576-583, 1999
35. Borkowsky W, Stanley K, Douglas SD, et al: Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy - Experienced human immunodeficiency virus-infected children. J Infect Dis 182:96-103, 2000
36. Faye A, Berone C, Teglas JP, et al: Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 21:518-525, 2002
37. Van Rossum AMC, Geelen SPM, Hartwig NG, et al: Results of two years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 34:1008-1016, 2002
38. Jankelevich S, Mueller BU, Mackall GL, et al: Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J Infect Dis 183:1116-1120, 2001
39. De Martino M, Galli L, Moriondo M, et al: Dissociation of responses to highly active antiretroviral therapy: Notwithstanding virologic failure and virus drug resistance, both CD4+ and CD8+ T lymphocytes recover in HIV-1 perinatally infected children. J Acquir Immune Defic Syndr 26:196-197, 2001
40. Essajee SM, Kim M, Gonazlez C, et al: Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 131:2523-2532, 1999
41. Funk MB, Linde R, Wintergerst U, et al: Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 13:1653-1658, 1999
42. Lemberg DA, Palasanthiram P, Goode M, et al: Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 25:973-991, 2002
43. King JR, Kimberlin DW, Aldrovandi GM, et al: Antiretroviral pharmacokinetics in the paediatric population. A review. Clin Pharmacokinet 41:1115-1133, 2002
44. Miller, V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 26:S34-S50, 2001 (suppl 1)
45. Decks, SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26:S25-S33, 2001 (suppl 1)
46. Loveday, C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26:S10-S24, 2001 (suppl 1)
47. Eshleman SH, Krogstad P, Jackson JB. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 183:1732-1738, 2001
48. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al: Drug resistance mutations in HIV-1. Top HIV Med 10:21-24, 2002
49. Hertogs K, Bloor S, Kemp SD, et al: Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross resistance: A survey of over 6000 samples. AIDS 14:1203-1210, 2000
50. Ometto L, De Forni D, Patiri F, et al: Immune reconstitution in HIV-1-infected children on antiretroviral therapy: Role of thymic output and viral fitness. AIDS 16:839-849, 2002
51. Nijhuis M, Deeks S, Boncher C: Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 14:23-28, 2001
52. Devereux HL, Emery VC, Johnson MA, et al: Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65:218-224, 2001
53. LeMoing V, Chene G, Carrieri MP, et al: Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen. AIDS 16:21-29, 2002
54. Staszewski S, Morales-Ramirez J, Tashima K, et al: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341:1865-1873, 1999
55. Capparelli EV, Micochnick M, Dankner WM, et al: Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 142:47-52, 2003
56. Schuster T, Linde R, Wintergerst U, et al: Nelfinavir pharmacokinetics in HIV-infected children: A comparison of twice daily and three times daily closing. AIDS 14:1466-1468, 2000
57. Capparelli EV, Sullivan JL, Mofenson L, et al: Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J 20:746-751, 2001
58. Kline MW, Brundage RC, Fletcher CV, et al: Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr Infect Dis J 20:666-671, 2001
59. Fletcher CV, Brundage RC, Remmel RP, et al: Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 1029-1034, 2000
60. Gatti G, Vigano A, Sala N, et al: Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 44:752-755, 2000
61. Treluyer JM, Burgard M, Cazali N, et al: Relationship between antiretroviral drug plasma concentrations and viral load in children. J Acquir Immune Defic Syndr 32:112-115, 2003
62. Back, D, Gatti, G, Fletcher, C, et al Therapeutic drug monitoring in HIV infection; Current status and future directions. AIDS 16:S5-S37, 2002 (suppl 1)
63. Fletcher CV, Anderson PL, Kakuda TN, et al: Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16:551-560, 2002
64. Paterson DL, Swindells S, Mohr J, et al: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21-30, 2000
65. Reddington C, Cohen J, Baldillo A, et al: Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 19:1148-1153, 2000
66. Van Dyke RB, Lee S, Johnson GM, et al: Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 109:1-7, 2002
67. Howard AA, Arnsten JH, Lo Y, et al: A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16:2175-2182, 2002
68. Wu AW, Ammassari A, Antinori A: Adherence to antiretroviral therapy: Where are we, and where do we go from here? J Acquir Immune Defic Syndr 31:S95-S97, 2002
69. Tuldra, A, Wu, AW Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 31: S154-S157, 2002 (suppl 3)
70. Shingadia D, Viani RM, Yogev R, et al: Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics 105:1-5, 2000
71. New York State Department of Health AIDS Institute: Pediatric antiretroviral therapy: Text, tables, and recommendations. March 2002. Available from URL: http://www.hivguidelines.org/
72. Havens, PL, Waters DA, Cuene BE, et al: Caring for Infants, Children, Adolescents, and Families with HIV Infection. Wisconsin Department of Health and Social Services, Division of Health, Publication POH 4498 (Rev. 01/01). Available from URL: http://www.mcw.edu/peds/infectdis
73. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1 specific immune responses. J Virol 74:6984-6991, 2000
74. Spiegel HML, Chandwani R, Sheehy IME, et al: The impact of early initiation of highly active antiretroviral therapy on human immunodeficiency virus type 1-specific CD8 T cell response in children. J Infect Dis 182:88-95, 2000
75. Hainaut M, Peltier CA, Gerard M, et al: Effectiveness of antiretroviral therapy initiated before the age of two months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 159:778-782, 2000
76. Munoz-Almagro C, Fortuny C, Juncosa T, et al: Absence of detectable HIV-1 provirus DNA after early highly active antiretroviral therapy in children infected by vertical transmission. J Acquir Immune Defic Syndr 31:450-452, 2002
77. Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep 43:1-10, 1994
78. Mofenson LM, Korelitz J, Meyer WA, et al: The relationship between human immunodeficiency virus type 1 RNA level, CD4 lymphocyte percent, and mortality risk in HIV-1 infected children. J Infect Dis 175:1029-1038, 1997
79. Egger M, May M, Chene G, et al: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119-129, 2002
80. Nikolic-Djokic D, Essajee S, Rigaud M, et al: Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis 185:290-298, 2002
81. Polis MA, Sidorov IA, Yoder C, et al: Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 358:1760-1766, 2001
82. Demeter LM, Hughes MD, Coombs RW, et al: Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann Intern Med 135:954-964, 2001
83. Schambelan M, Benson CA, Carr A, et al: Management of metabolic complications with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31257-3275, 2002
84. Lewis W, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 1:417-422, 1995
85. Church JA, Mitchell WG, Gonzalez-Gomez I, et al: Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 138:71-8751, 2001
86. Blanche S, Tardieu IM, Rustin P, et al: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089, 1999
87. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 16:F1-F8, 2002
88. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 25:213-229, 2002
89. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
90. American Academy of Pediatrics: Committee on Nutrition. Cholesterol in childhood. Pediatrics 101:145-147, 1998
91. Carr, A HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30:S135-S142, 2000 (suppl 2)
92. Amaya RA, Kozinetz CA, McMeans A, et al: Lipodystrophy syndrome in human immunodeficiency virus-infected children. Ped Infect Dis J 21:405-410, 2002
93. Jaquet D, Levine M, Ortega-Rodriguez E, et al: Clinical and maetabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14:2123-2128, 2000
94. Brambilla P, Bricalli D, Sala N, et al: Flighty active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 15:2415-2422, 2001
95. Arpadi SM, Cuff PA, Horlick MLipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 27:30-34, 2001
96. Seidell JC, Bakker CJ, van der Kooy K: Imaging techniques for measuring adipose-tissue distribution: A comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr 51:953-957, 1990
97. Miller KD, Jones E, Yanovski JA, et al: Visceral abdominal fat accumulation associated with use of indinavir. Lancet 351:871-875, 1998
98. Cheue G, Angelini E, Cotte L, et al: Role of long-term nucleoside analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 34:649-657, 2002
99. Carr A, Miller J, Law M, et al: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to inhibitor-related lipodystrophy syndrome. AIDS 14:F25-F32, 2000
100. Estrada V, Serrano-Rios M, Martinez Larrad MT, et al: Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 29:32-40, 2002
101. Cherry CL, Gahan ME, McArthur JC, et al: Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30:271-277, 2002
102. Cossarizza A, Mussini C, Vigano A: Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: Actors or bystanders? BioEssays 23:1070-1080, 2001
103. Cossarizza A, Piuti M, Moretti LMitochondrial functionally and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-Positive Children with highly active antiretroviral therapy-Related lipodystrophy. J Infect Dis 185:299-305, 2002
104. Martin-ElRoche R, Poizot-Martin I, et al: Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16:13-20, 2002
105. Mora S, Sala N, Bricalli D, et al: Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15:1823-1829, 2001
106. Martinez E, Conget I, Lozano L, et al: Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13:805-810, 1999
107. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14:807-812, 2000
108. Roubenoff R, Weiss L, McDermott A, et al: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13:1373-1375, 1999
109. Roubenoff R, Schmitz H, Bairos L, et al: Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: Case report and proof of principle. Clin Microbiol Infect Dis 34:390-393, 2002
110. Arpadi SM, Horlick M, Thornton J, et al: Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 29:450-454, 2002
111. Allison GT, Bostrom MP, Glesby MJ: Osteonecrosis in HIV disease: Epidemiology, etiologies, and clinical management. AIDS 17:1-9, 2003
112. Lawal A, Engelson ES, Wang J, et al: Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 15:278-280, 2001
113. Gaughan DIM, Mofenson LM, Hughes MD, et al: Osteonecrosis of the hip (Legg-Calve-Perthes disease) in human immunodeficiency virus-infected children. Pediatrics 109:E74-E4, 2002
114. Gutierrez F, Padilla S, Ortega E, et al: Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors. AIDS 16:481-483, 2002
115. Scribner AN, Troia-Cancio PV, Cox BA, et al: Osteonecrosis in HIV: A case-control study. J Acquir Immune Defic Syndr 25:19-25, 2000
116. Mondy K, Yarasheski K, Powderly WG, et al: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 313:482-490, 2003